Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lattice Biologics Ltd V.LBL.H

Alternate Symbol(s):  LBLTF

Healthcare Medical Devices
Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.


TSXV:LBL.H - Post by User

Lattice Biologics Ltd > Live depiction of Mesenchymal MSC
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(35)
•••
Comment by gainwidpatienceon May 17, 2020 10:51pm
72 Views
Post# 31041013

RE:RE:RE:RE:RE:RE:RE:RE:Live depiction of Mesenchymal MSC

RE:RE:RE:RE:RE:RE:RE:RE:Live depiction of Mesenchymal MSCBoobah.. There are few things to look at on this:

- I believe CEO has been so far bit poor in terms of planing and communication.
- Alumina deal seems to be a wrong step. With all the hype in March, their original pp at $0.10 would have been closed easily.
- In 2 months, LBL should have been entered into a collaboration with medical research companies/labs/universities for patients enrolment and assistance with clinical trials. I am quite critical on CEO being very slow with this.

But,
- Amnio Boost is being tried on 'humans'.. FDA wouldn't have allowed for this clinical trial unless they see eligibility of this therapy for trying on humans. Nobody would like to risk their life.
- None of the studies/trials of MSC conducted on covid patients with ARDS are failed.  Therefore, probability of failure in Ph1 is unlikely.
- Market capitalization is way too low. Once they announce ph1 results successful, sp will shoot up. But, they should do it asap or else competitors will run over it.

Therefore, I am giving some time here.. willing to wait for their milestones.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities